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Immune checkpoint blockers can achieve durable clinical responses in at least one‐fifth of patients with various types of advanced cancer.[1](#cas12919-bib-0001){ref-type="ref"}, [2](#cas12919-bib-0002){ref-type="ref"} However, clinical benefits cannot be expected in cancer patients whose tumors display no or few tumor‐infiltrating lymphocytes. We previously reported that personalized peptide vaccination rapidly induced the proliferation of CD45RO^+^‐activated lymphocytes at tumor sites, in association with various clinical benefits, in patients with advanced cancer.[3](#cas12919-bib-0003){ref-type="ref"}, [4](#cas12919-bib-0004){ref-type="ref"} These results suggest that the combined therapy of a cancer vaccine and immune checkpoint blockers could be more efficacious than monotherapy.

In contrast to immune checkpoint blockers, however, cancer vaccines tested in the past two decades have not yet yielded optimal clinical outcomes for drug approval.[5](#cas12919-bib-0005){ref-type="ref"}, [6](#cas12919-bib-0006){ref-type="ref"}, [7](#cas12919-bib-0007){ref-type="ref"} The large heterogeneity of tumor‐associated antigens and the diversity in both human leukocyte antigen (HLA) and T cell subsets may hamper the successful development of a cancer vaccine.[8](#cas12919-bib-0008){ref-type="ref"}, [9](#cas12919-bib-0009){ref-type="ref"}

An appropriate dose setting for each vaccine, as well as suitable predictive biomarkers in early phase studies, may have hampered previous trials to address clinical benefits.[5](#cas12919-bib-0005){ref-type="ref"}, [6](#cas12919-bib-0006){ref-type="ref"}, [7](#cas12919-bib-0007){ref-type="ref"}, [8](#cas12919-bib-0008){ref-type="ref"}, [9](#cas12919-bib-0009){ref-type="ref"} To overcome these problems, we have aimed to develop a new type of CTL‐epitope peptide vaccine consisting of 10 mixed peptides (KRM‐10) that can be applied to the vast majority of cancer patients with different HLA alleles, including the HLA‐A2, A24 and A3 supertypes (A3, A11, A31 and A33) or A26. This study presents the results of a phase I study of peptide vaccination using these 10 peptides that were frequently chosen in previous clinical trials of personalized peptide vaccination for patients with advanced cancers.[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}

Patients and Methods {#cas12919-sec-0002}
====================

Patients and eligibility {#cas12919-sec-0003}
------------------------

Eligible patients were aged between 20 and 80 years, with histologically confirmed gastrointestinal cancer, for whom standard therapies were ineffective or inappropriate. Patients were required to have a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group performance status of 0--1, the ability to eat, and adequate organ function as assessed by a platelet (≥75 000/mm^3^) count, an absolute lymphocyte (≥1000/mm^3^) count, serum total bilirubin (≤2.0 mg/dL), serum creatinine (≤1.5 mg/dL) and alanine aminotransferase and aspartate aminotransferase (≤100 IU/L, or ≤200 IU/L in patients with hepatic metastasis) levels. Having a target lesion or lesions according to the response evaluation criteria for solid tumors was not mandatory. Exclusion criteria included patients with active infection, significant cardiovascular disease, psychogenic disorders, uncontrolled diabetes, pulmonary fibrosis or active pneumonitis, treatment with systemic corticosteroids, active gastrointestinal bleeding, treatment for pleural effusions and/or ascites, active concomitant malignancy, pregnancy or lactation, and hepatitis B infection. This study was approved by the Institutional Review Board of the National Cancer Center, Tokyo, Japan and conducted in accordance with the Declaration of Helsinki. All patients provided written, informed consent prior to study entry. This study was registered with the UMIN Clinical Trials Registry as UMIN000008820.

Study design and vaccinations {#cas12919-sec-0004}
-----------------------------

This was an open‐label, single‐center, phase I, dose‐escalation study undertaken to determine the recommended dose of KRM‐10 based on its dose‐limiting toxicity (DLT) and immunological response. The primary objective was to identify the maximum tolerated dose (MTD) of KRM‐10. Secondary objectives were to assess safety and immune responses as assessed by peptide‐specific immunoglobulin (IgG) and CTL levels. The KRM‐10 vaccine was supplied by the Kurume University School of Medicine (Fukuoka, Japan).

Patients were injected subcutaneously with the KRM‐10 vaccine at a dose of 10 mg/0.5 mL (1 mg of each peptide), 20 mg/1.0 mL (2 mg of each peptide) or 30 mg/1.5 mL (3 mg of each peptide), once a week for 6 weeks. These three dose levels were chosen based on a previously conducted personalized peptide vaccine study in which 3 mg of each peptide (total of four peptides per injection) was considered an acceptable dose according to safety and immunological responses.[13](#cas12919-bib-0013){ref-type="ref"} The sample size for each cohort was six on completion of the protocol treatment, allowing the adequate evaluation of safety and tolerability while minimizing exposure to a new cancer vaccine.

Dose‐limiting toxicities were defined as any of the following events that were considered by the investigator to be related to the KRM‐10 treatment and which occurred up until the end of the first week after the sixth vaccination, irrespective of whether the observed adverse events were eliminated or reduced: grade 3 skin induration; skin ulceration; injection site reaction; other non‐hematological grade 3 or 4 toxicities except for anorexia, nausea, vomiting and fatigue, constipation and dehydration; hyperglycemia; and electrolyte abnormality.

Patients with non‐progressive disease (PD), after a protocol treatment period involving the six KRM‐10 vaccinations, were allowed to continue with KRM‐10 treatment on compassionate grounds until disease progression. During this period of continued use, patients were allowed to receive the vaccine six times every 2 weeks, followed by six times every 4 weeks, up to a total of 18 times.

Peptides {#cas12919-sec-0005}
--------

KRM‐10 consisted of the following 10 peptides: SART3~302--310~, Lck~246--254~ and HNRPL~140--148~ for patients with HLA‐A2; Lck~488--497~, MRP3~503--511~ and EGFR~800--809~ for patients with HLA‐A24; SART3~734--742~, and Lck~90--99~ for patients with the HLA‐A3 supertype; SART3~109--118~ for patients with the HLA‐A24 and HLA‐A3 supertypes or HLA‐A26; and WHSC2~103--111~ for HLA‐A2 and HLA‐A3 supertypes or HLA‐A26; their abilities to induce HLA‐class IA‐restricted CTL activity have been reported previously.[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}, [14](#cas12919-bib-0014){ref-type="ref"} These 10 peptides were prepared under the conditions outlined by the code of Good Manufacturing Practice using an automated multiple peptide synthesizer (Multiple Peptide Systems, San Diego, CA, USA) and the services of the American Peptide Company (Vista, CA, USA). Ten peptides were mixed with Incomplete Freund\'s adjuvant (Montanide ISA‐51VG; Seppic, Paris, France).

Although the HLA types were shown at two digits in this study, we had reported that the 10 peptides employed are applicable to patients with HLA‐A2404, HLA‐A0201, HLA‐A0206, HLA‐A0207, HLA‐A1101, HLA‐A3101, HLA‐A3303, HLA‐A2601, HLA‐A2602 or HLA‐A2603 at four digits. The HLA restriction of 10 peptides of KRM‐10 are shown in Table S1. Because these four‐digit HLA types are expected to cover 99.94% of the Japanese population, we think that it could be worthwhile using these 10 peptides for all Japanese patients without screening for HLA genotypes.

Prior to the initiation of this phase I study, we had tested the CTL and IgG responses to more than 500 peptide candidates derived from the six mother antigens using pre‐vaccination samples of cancer patients, as reported previously.[11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"} The 10 peptides employed in the present study were chosen from those \>500 peptides based upon the higher reactivity in pre‐vaccination samples of advanced gastrointestinal cancer patients with regard to peptide‐specific CTL and IgG responses. In addition, both CTL and IgG responses to these 10 peptides were shown to be well boosted after vaccination in patients enrolled in the phase II clinical trials of personalized peptide vaccinations as reported previously.[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}, [13](#cas12919-bib-0013){ref-type="ref"}, [14](#cas12919-bib-0014){ref-type="ref"}, [15](#cas12919-bib-0015){ref-type="ref"} Therefore, these 10 peptides of KRM‐10 might be recognized by the immune system of pre‐vaccination patients with advanced gastrointestinal cancers through natural presentation to peptide‐reactive T and B cells.

It might be important to examine the expression of molecules, from which each peptide is derived, in the original tumors in each patient. However, we could not test the original tumors, mainly because surgical tumor samples or biopsy samples just before or after vaccination were unavailable from most of the enrolled patients with far advanced gastrointestinal cancers, who had no surgical indication. Instead, we examined the expression of six different mother antigens in resected tumors from non‐vaccinated esophageal (*n* = 10), gastric (*n* = 15) or colorectal (*n* = 10 or *n* = 15)[10](#cas12919-bib-0010){ref-type="ref"} cancer patients (Table [1](#cas12919-tbl-0001){ref-type="table-wrap"}). Representative results of immunohistochemical staining are shown in Figure [1](#cas12919-fig-0001){ref-type="fig"}. All of the six mother antigens were expressed in adenocarcinoma tissues from gastric and colorectal cancer patients at different frequencies, but 2 of 6 antigens (LCK and MRP3) were not detectable in any of 10 squamous cell carcinoma tissues tested from esophageal cancer patients.

###### 

Expression of original proteins in esophageal, gastric or colorectal tumors

  Original protein   Peptide name   Esophagus[a](#cas12919-note-0002){ref-type="fn"}   Stomach[a](#cas12919-note-0002){ref-type="fn"}   Colorectum[a](#cas12919-note-0002){ref-type="fn"}
  ------------------ -------------- -------------------------------------------------- ------------------------------------------------ ---------------------------------------------------
  EGFR               EGF‐R‐800      8/10 (80%)                                         9/15 (60%)                                       8/15 (53%)
  HNRPL              HNRPL‐140      10/10 (100%)                                       15/15 (100%)                                     10/10 (100%)
  p56Lck             Lck‐90         0/10 (0%)                                          1/15 (7%)                                        4/15 (27%)
                     Lck‐246                                                                                                            
                     Lck‐488                                                                                                            
  MRP3               MRP3‐503       0/10 (0%)                                          9/15 (60%)                                       9/15 (60%)
  SART3              SART3‐109      10/10 (100%)                                       15/15 (100%)                                     10/10 (100%)
                     SART3‐302                                                                                                          
                     SART3‐734                                                                                                          
  WHSC2              WHSC2‐103      9/10 (90%)                                         15/15 (100%)                                     10/10 (100%)

Frequency of original protein expression (positive cases/examined cases \[percentage\]) was determined by immunohistochemistry in resected tumors from non‐vaccinated esophageal (*n* = 10), gastric (*n* = 15) or colorectal (*n* = 10 or *n* = 15) cancer patients.

John Wiley & Sons, Ltd

![The expression levels of the six vaccine antigens that code the peptides were examined by immunohistochemical staining in tumor tissues from non‐vaccinated esophageal (*n* = 10), gastric (*n* = 15) or colorectal (*n* = 10 or *n* = 15) cancer patients.[10](#cas12919-bib-0010){ref-type="ref"} Paraffin‐embedded tissue samples were cut into 4‐μm sections, and examined on a coated slide glass. Detailed methods including the antibodies used for immunohistochemistry (IHC) have been described previously.[10](#cas12919-bib-0010){ref-type="ref"}, [15](#cas12919-bib-0015){ref-type="ref"} Representative results of immunohistochemical staining are shown: (a) esophageal cancer; (b) gastric cancer and (c) colorectal cancer.](CAS-107-590-g001){#cas12919-fig-0001}

Measurement of cytotoxic T lymphocytes and immunoglobulin G, and soluble inflammatory factors {#cas12919-sec-0006}
---------------------------------------------------------------------------------------------

Cytotoxic T lymphocyte activity specific to each of the HLA‐matched peptides and the 10 mixed peptides (KRM‐10) was evaluated by interferon‐γ (IFN‐γ) enzyme‐linked immunospot (ELISPOT) assay using peripheral blood mononuclear cell (PBMC) as reported previously.[10](#cas12919-bib-0010){ref-type="ref"}, [14](#cas12919-bib-0014){ref-type="ref"} All assays were carried out in triplicate and analyzed with an ELISPOT reader (CTL‐ImmunoSpot S5 Series; Cellular Technology, Shaker Heights, OH, USA). CTL activity was evaluated by the difference between spot numbers in response to the corresponding peptide and those of the control peptide. The cut‐off level was set as 10 IFNγ‐spots per 10^5^ PBMC. If the spot numbers, in response to the corresponding peptide in post‐vaccination PBMC, were more than twofold higher than those in pre‐vaccination PBMC, the changes were considered to be positive immune responses, as reported previously.[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}, [13](#cas12919-bib-0013){ref-type="ref"}, [14](#cas12919-bib-0014){ref-type="ref"}, [15](#cas12919-bib-0015){ref-type="ref"} The changes were also considered to be positive if the spot numbers were under 10 in the pre‐vaccination samples and became detectable after the vaccination. An IgG response specific to HLA‐matched peptides was determined by peptide‐specific IgG levels using a Luminex system (Luminex, Austin, TX, USA).[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}, [13](#cas12919-bib-0013){ref-type="ref"}, [14](#cas12919-bib-0014){ref-type="ref"}, [15](#cas12919-bib-0015){ref-type="ref"} The cut‐off level of FIU titers was set as 10. If titers of peptide‐specific IgG in the post‐vaccination plasma were more than twofold higher than those in the pre‐vaccination plasma, the increases were considered to be positive immune responses, as reported previously.[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}, [13](#cas12919-bib-0013){ref-type="ref"}, [14](#cas12919-bib-0014){ref-type="ref"}, [15](#cas12919-bib-0015){ref-type="ref"}

Acute‐phase inflammatory factors (C‐reactive protein, haptoglobin, beta2‐microglobulin and Gc globulin) in pre‐vaccination and post‐vaccination plasmas were examined in the present study using Invitrogen\'s Multiplex Bead Immunoassay Kit (Invitrogen Thermo Fisher Scientific, Waltham, MA, USA). Frozen plasma samples were thawed, diluted and assayed in accordance with the manufacturer\'s instructions. If the levels of inflammatory factors in the post‐vaccination plasma were more than twofold higher than those in the pre‐vaccination plasma, the increases were considered to be significant.

Safety and tumor assessments {#cas12919-sec-0007}
----------------------------

Adverse events were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 throughout the treatment period until a minimum of 28 days after the last dose, or until all drug‐related adverse events had recovered to baseline or were deemed irreversible. Tumor assessments by computed tomography or magnetic resonance imaging scans were carried out at baseline and after the sixth vaccination, and evaluated according to the Response Evaluation Criteria In Solid Tumors version 1.1.[16](#cas12919-bib-0016){ref-type="ref"}

Statistical analysis {#cas12919-sec-0008}
--------------------

All patients who received vaccinations were included in the analysis of its safety and efficacy. All statistical analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC, USA).

Results {#cas12919-sec-0009}
=======

Patient characteristics {#cas12919-sec-0010}
-----------------------

Twenty‐one patients were enrolled in this study: 6, 8 and 7 patients received 10, 20 and 30 mg of KRM‐10 vaccine (1, 2 or 3 mg of each peptide, respectively) once a week for 6 weeks, respectively. Patient characteristics are shown in Table [2](#cas12919-tbl-0002){ref-type="table-wrap"}. HLA‐class IA types determined by genotyping were A24 (*n* = 10), A2 (9), A31 (6), A26 (4), A33 (3), A11 (2) and A3 (1). At least four peptides of the 10 mixed peptides were matched in each of the 20 patients with 4 peptides for 11 patients, 5 for 2, 7 for 3, and 8 for 4 patients (Table [3](#cas12919-tbl-0003){ref-type="table-wrap"}). Eighteen patients completed the protocol treatment as planned in the 6‐week period; three patients discontinued treatment due to early tumor progression and were excluded from subjects used to assess DLT: 2 in the 20 mg, and 1 in the 30‐mg cohort. The median number of vaccinations for the 10, 20 and 30‐mg cohorts was 6 (range 6--14), 6 (range 3--9) and 6 (range 2--17), respectively.

###### 

Baseline characteristics

                                       10‐mg peptide (*n* = 6)   20‐mg peptide (*n* = 8)   30‐mg peptide (*n* = 7)
  ------------------------------------ ------------------------- ------------------------- -------------------------
  Gender, *n* (%)                                                                          
  Male                                 5                         5                         4
  Female                               1                         3                         3
  Age, years                                                                               
  Median (range)                       71.5 (63--77)             65.5 (49--77)             65 (59--74)
  ECOG PS, *n* (%)                                                                         
  0                                    2                         5                         2
  1                                    4                         3                         5
  HLA expression, *n* (%)                                                                  
  HLA‐A2                               5                         2                         2
  HLA‐A3                               1                         0                         0
  HLA‐A11                              0                         1                         1
  HLA‐A24                              3                         4                         3
  HLA‐A26                              0                         1                         3
  HLA‐A31                              2                         1                         3
  HLA‐A33                              2                         1                         0
  Previous therapy, *n* (%)                                                                
  Chemotherapy                         6                         8                         7
  Radiotherapy                         3                         1                         2
  Surgery                              3                         8                         4
  Chemotherapy                                                                             
  1 regimen                            1                         0                         1
  2 regimens                           1                         0                         1
  3+ regimens                          4                         8                         5
  Type of tumor, *n* (%)                                                                   
  Esophageal squamous cell carcinoma   4                         0                         0
  Gastric adenocarcinoma               2                         1                         1
  Small intestinal adenocarcinoma      0                         1                         0
  Colorectal adenocarcinoma            0                         6                         4
  Anal canal squamous cell carcinoma   0                         0                         1

ECOG, Eastern Cooperative Oncology Group; HLA, human leukocyte antigens; PS, performance status.
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###### 

Immune responses

  Pt no.   Dose of KRM‐10 (mg)   HLA type   HLA matching peptides or KRM10   CTL response (pg/mL)   IgG response (FIU)   Response   OS(m)                       
  -------- --------------------- ---------- -------------------------------- ---------------------- -------------------- ---------- ------- ------ ------- ---- ------
  L1‐1     10                    A33        WHSC2‐103                        0                      0                    0          0       0      0       SD   13.9
                                            SART3‐734                        0                      0                    0          159     147    156          
                                            Lck‐90                           0                      28                   0          0       0      0            
                                            SART3‐109                        0                      18                   0          0       0      0            
                                            KRM‐10                           0                      22                   0          ND      ND     ND           
  L1‐2     10                    A2/A24     SART2‐302                        0                      0                    0          42      58     92      PD   8.7
                                            Lck‐246                          0                      0                    0          0       0      0            
                                            WHSC2‐103                        0                      0                    0          0       0      0            
                                            HNRPL‐140                        0                      0                    0          0       0      0            
                                            EGFR‐800                         0                      0                    0          0       0      0            
                                            SART3‐109                        0                      0                    0          0       0      0            
                                            Lck‐488                          0                      0                    0          0       0      0            
                                            MRPP3‐503                        0                      0                    227        0       0      0            
                                            KRM‐10                           0                      0                    260        ND      ND     ND           
  L1‐3     10                    A11/A31    WHSC2‐103                        0                      0                    0          0       0      0       PD   2.5
                                            SART3‐734                        0                      0                    0          5939    3685   2456         
                                            Lck‐90                           0                      0                    0          0       0      0            
                                            SART3‐109                        0                      0                    0          0       0      0            
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L1‐4     10                    A2/A24     SART3‐302                        0                      0                    0          0       0      0       SD   20.1
                                            Lck‐246                          0                      0                    0          0       0      0            
                                            WHSC2‐103                        0                      0                    0          0       0      0            
                                            HNRPL‐140                        0                      0                    0          0       0      0            
                                            EGFR‐800                         0                      0                    0          0       0      0            
                                            SART3‐109                        0                      0                    0          0       0      0            
                                            Lck‐488                          0                      0                    0          0       0      0            
                                            MRP3‐503                         0                      0                    33         0       0      0            
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L1‐5     10                    A24        EGFR‐800                         0                      0                    0          0       0      0       PD   7.6
                                            SART3‐109                        0                      0                    0          0       0      0            
                                            Lck‐488                          0                      0                    0          0       0      0            
                                            MRP3‐503                         0                      0                    0          0       0      0            
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L1‐6     10                    A24/A26    EGFR‐800                         0                      0                    0          0       0      0       PD   3.0
                                            SART3‐109                        0                      0                    0          0       21     25           
                                            Lck‐488                          20                     0                    0          74      130    123          
                                            MRP3‐503                         0                      74                   42         111     141    144          
                                            WHSC2‐103                        0                      0                    0          0       10     0            
                                            KRM‐10                           0                      59                   30         ND      ND     ND           
  L2‐1     20                    A3/A33     WHSC2‐103                        0                      0                    32         0       0      0       PD   7.6
                                            SART3‐734                        0                      0                    131        22      44     18           
                                            Lck‐90                           26                     0                    0          0       0      0            
                                            SART3‐109                        0                      0                    0          0       0      1090         
                                            KRM‐10                           0                      241                  148        ND      ND     ND           
  L2‐2     20                    A2         SART3‐302                        0                      0                    --         20      22     --      PD   3.4
                                            Lck‐246                          0                      0                    --         0       0      --           
                                            WHSC2‐103                        0                      0                    --         0       0      --           
                                            HNRPL‐140                        0                      0                    --         0       0      --           
                                            KRM‐10                           0                      0                    --         ND      ND     --           
  L2‐3     20                    A31        WHSC2‐103                        0                      0                    0          0       14     19      PD   9.8
                                            SART3‐734                        0                      0                    0          0       36     36           
                                            Lck‐90                           0                      0                    0          0       16     41           
                                            SART3‐109                        0                      0                    0          0       0      24           
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L2‐4     20                    A2/A33     SART3‐302                        0                      0                    0          0       0      0       SD   5.1
                                            Lck‐246                          0                      0                    0          0       0      0            
                                            WHSC2‐103                        22                     0                    0          15      14     0            
                                            HNRPL‐140                        0                      0                    24         27      20     0            
                                            SART3‐734                        0                      0                    0          14      11     0            
                                            Lck‐90                           0                      0                    0          32      27     135          
                                            SART3‐109                        0                      0                    0          14      0      0            
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L2‐5     20                    A11        SART3‐302                        0                      0                    0          1682    1595   1088    PD   4.0
                                            Lck‐246                          0                      0                    0          16      11     22           
                                            WHSC2‐103                        0                      0                    0          24      19     23           
                                            HNRPL‐140                        0                      20                   16         20      15     16           
                                            EGFR‐800                         0                      0                    0          13      11     11           
                                            SART3‐109                        0                      0                    0          20      12     23           
                                            Lck‐488                          0                      82                   0          74      62     61           
                                            MRP3‐503                         0                      131                  134        13      10     148          
                                            KRM‐10                           0                      194                  177        ND      ND     ND           
  L2‐6     20                    A24        EGFR‐800                         0                      0                    --         77      73     --      PD   1.4
                                            SART3‐109                        0                      0                    --         75      79     --           
                                            Lck‐488                          0                      59                   --         429     410    --           
                                            MRP3‐503                         0                      0                    --         37      39     --           
                                            KRM‐10                           0                      0                    --         ND      ND     --           
  L2‐7     20                    A11/A31    WHSC2‐103                        0                      0                    0          18      14     13      SD   19.9
                                            SART3‐734                        0                      0                    0          8125    8454   8639         
                                            Lck‐90                           0                      0                    0          18      17     22           
                                            SART3‐109                        0                      0                    0          16      14     14           
                                            KRM‐10                           0                      31                   0          ND      ND     ND           
  L2‐8     20                    A24        EGFR‐800                         0                      0                    0          0       0      0       PD   6.6
                                            SART3‐109                        0                      0                    0          0       0      0            
                                            Lck‐488                          0                      0                    0          42      34     30           
                                            MRP3‐503                         0                      0                    42         0       0      0            
                                            KRM‐10                           0                      0                    57         ND      ND     ND           
  L3‐1     30                    A2/A31     SART3‐302                        0                      0                    0          273     243    24947   PD   6.2
                                            Lck‐246                          0                      0                    0          0       0      0            
                                            WHSC2‐103                        0                      0                    0          12      10     11           
                                            HNRPL‐140                        0                      0                    0          11      9      10           
                                            SART3‐734                        0                      0                    0          57      43     80           
                                            Lck‐90                           0                      0                    0          24      21     566          
                                            SART3‐109                        0                      0                    0          10      0      10           
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L3‐2     30                    A26/A31    WHSC2‐103                        0                      82                   0          0       0      0       PD   3.7
                                            SART3‐109                        0                      0                    0          0       10     11           
                                            SART3‐734                        0                      0                    0          1206    975    454          
                                            Lck‐90                           0                      0                    0          23      30     565          
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L3‐3     30                    A2/A24     SART3‐302                        0                      0                    0          1337    1715   814     PD   12.8
                                            Lck‐246                          0                      0                    0          19      20     11           
                                            WHSC2‐103                        0                      0                    0          24      26     20           
                                            HNRPL‐140                        91                     0                    0          22      26     18           
                                            EGFR‐800                         0                      0                    0          18      17     14           
                                            SART3‐109                        0                      0                    0          21      26     19           
                                            Lck‐488                          0                      0                    0          98      108    93           
                                            MRP3‐503                         0                      0                    0          15      18     12           
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L3‐4     30                    A24/A33    EGFR‐800                         0                      0                    84         0       0      0       PD   10.2
                                            SART3‐109                        0                      0                    0          0       0      0            
                                            Lck‐488                          0                      0                    0          18      11     15           
                                            MRP3‐503                         0                      0                    0          0       0      0            
                                            WHSC2‐103                        0                      0                    0          17      11     11           
                                            SART3‐734                        0                      0                    0          3049    2124   3182         
                                            Lck‐90                           0                      0                    0          0       0      0            
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L3‐5     30                    A24/A26    EGFR‐800                         0                      0                    0          0       0      0       SD   16.6
                                            SART3‐109                        0                      0                    0          932     833    480          
                                            Lck‐488                          0                      0                    0          743     652    405          
                                            MRP3‐503                         0                      0                    0          643     560    320          
                                            WHSC2‐103                        0                      0                    0          74      61     0            
                                            KRM‐10                           0                      0                    0          ND      ND     ND           
  L3‐6     30                    A26/A31                                     NA                     NA                   NA         NA      NA     NA      PD   6.1
  L3‐7     30                    A11        WHSC2‐103                        0                      0                    0          19      20     21      PD   10.8
                                            SART3‐734                        0                      0                    0          1042    1010   1003         
                                            Lck‐90                           0                      12                   0          22      22     23           
                                            SART3‐109                        0                      0                    0          0       0      11           
                                            KRM‐10                           0                      0                    0          ND      ND     ND           

A blood test was performed after the third/sixth vaccination or disease progression, whichever occurred first. Pt no., patient number; OS(m), overall survival (months); SD, stable disease; PD, progressive disease; CTL, cytotoxic T lymphocytes; FIU, fluorescent intensity units; ND, not detected; NA, not available. --, Cases with the dashes had no post sixth sample.
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Safety and tolerability {#cas12919-sec-0011}
-----------------------

No DLT were reported in this study. Adverse events are summarized in Table [4](#cas12919-tbl-0004){ref-type="table-wrap"}. The most frequent treatment‐related adverse event was a dermatological reaction to the peptide vaccine at injection sites in 15 patients (71%) and fever in three patients (14%). Two patients had either a grade 2 herpes zoster or herpes labialis. No treatment‐related serious adverse events were observed. One patient in the 20‐mg cohort experienced a serious adverse event (increased grade 3 bilirubin) that was considered to be due to disease progression, not vaccination, by the independent review board.

###### 

Adverse event

                                 10‐mg peptide   20‐mg peptide   30‐mg peptide   Total                                    
  ------------------------------ --------------- --------------- --------------- ------- --- --- --- --- --- ---- --- --- ----------
  Any AE                                                                                                                  
  Anemia                         4               2                               5               4           13   2       15 (71%)
  Injection site skin reaction   5                                               7               3           15           15 (71%)
  Fever                          2                                                                   1       2    1       3 (14%)
  Increased ALT and AST          1                                               1       1       1   1       3    2       5 (24%)
  Blood bilirubin increased                                                                  1       1            1   1   2 (9%)
  Hyponatremia                   4                                               3               2           9            9 (43%)
  Diarrhea                                                                       2                           2            2 (9%)
  Bladder infection                                                                      1                        1       1 (5%)
  Dysgeusia                                                                      1                           1            1 (5%)
  Hoarseness                     1                                                                           1            1 (5%)
  Bronchopulmonary hemorrhage    1                                                                           1            1 (5%)
  Neuropathy‐sensory             1                                                                           1            1 (5%)
  Increased creatinine           2                                               1               1           4            4 (19%)
  Herpes labialis                                                                        1                        1       1 (5%)
  Herpes zoster                                  1                                                                1       1 (5%)
  Treatment‐related AE                                                                                                    
  Fever                          2                                                                   1       2    1       3 (14%)
  Injection site skin reaction   5                                               7               3           15           15 (71%)
  Dysgeusia                                                                      1                           1            1 (5%)
  Bladder infection                                                                      1                        1       1 (5%)
  Herpes labialis                                                                        1                        1       1 (5%)
  Herpes zoster                                  1                                                                1       1 (5%)

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; G, grade.
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Cytotoxic T lymphocytes and immunoglobulin G responses, and inflammatory cytokines {#cas12919-sec-0012}
----------------------------------------------------------------------------------

Cytotoxic T lymphocyte responses to each of the vaccinated peptides were detectable in only 4 of 20 patients, with 4 of 111 peptides tested prior to vaccination (Table [3](#cas12919-tbl-0003){ref-type="table-wrap"}). However, CTL activity to at least one peptide at the third and sixth vaccination increased in 2 and 3 of 6 (10 mg), 2 of 8 and 4 of 6 (20 mg), or 2 and 1 of 6 (30 mg) patients, respectively. In addition, CTL activity to the 10‐peptide mix was increased in 2 and 2 of 6 (10 mg), 3 of 8 and 3 of 6 (20 mg), or 0 and 0 of 6 (30 mg**)** patients tested, respectively. IgG levels at the third and sixth vaccinations were also increased in 1 and 1 of 6 (10 mg), 2 of 8 and 4 of 6 (20 mg), or 1 and 3 of 6 (30 mg) patients, respectively. C‐reactive protein levels at the time of the sixth vaccination increased in 2 of 5, 1 of 6 or 1 of 6 patients receiving 10, 20 or 30 mg of peptides, while haptoglobin levels increased in 2, 0 or 0 patients receiving 10, 20 or 30 mg of peptides, respectively (Table [5](#cas12919-tbl-0005){ref-type="table-wrap"}). Beta2‐microglobulin and Gc globulin increased in 2 and 3 of 5 patients tested in the 10‐mg cohort, respectively, but not in the other cohorts.

###### 

Soluble inflammatory factors

  Pt no.   C‐reactive protein   Haptoglobin   Beta‐2 microglobulin   Gc globulin                                                        
  -------- -------------------- ------------- ---------------------- ------------- -------- -------- ------ ------ ------ ------ ------ ------
  L1‐1     0.56                 0.19          2.96                   379.3         668.9    966.6    10.2   19.6   22.7   8.7    21.2   21.2
  L1‐2     0.08                 0.04          0.07                   3118.8        2946.8   1921.1   10.1   9.1    8.6    21.2   15.8   7.0
  L1‐3     0.91                 1.39          2.96                   1762.7        2798.0   3430.1   8.2    10.4   12.2   8.4    16.0   17.7
  L1‐4     0.05                 0.06          0.08                   1536.3        1749.1   3236.4   9.9    13.6   22.8   10.5   12.7   21.2
  L1‐5     0.14                 NA            NA                     2167.8        NA       NA       21.9   NA     NA     14.3   NA     NA
  L1‐6     0.66                 0.88          1.00                   964.8         1172.5   1104.0   21.9   21.1   15.9   21.2   20.3   16.4
  L2‐1     0.32                 0.17          0.25                   699.7         444.4    613.1    7.4    4.5    6.2    9.9    4.1    6.3
  L2‐2     0.07                 0.11          NA                     730.2         1157.9   NA       7.0    8.2    NA     4.7    5.2    NA
  L2‐3     0.03                 0.01          0.03                   1054.2        479.1    639.8    4.3    2.3    2.6    13.0   4.0    4.6
  L2‐4     0.98                 0.12          0.18                   1559.0        735.1    680.8    8.5    4.6    4.5    10.4   5.1    4.2
  L2‐5     0.01                 0.12          0.06                   614.1         611.6    581.1    2.3    3.3    2.3    4.5    3.9    3.7
  L2‐6     1.16                 2.99          NA                     1396.2        984.3    NA       7.2    9.0    NA     4.4    2.3    NA
  L2‐7     1.90                 17.60         2.00                   1180.0        1950.0   1540.0   NA     NA     NA     NA     NA     NA
  L2‐8     0.70                 1.10          148.10                 1480.0        1510.0   1970.0   NA     NA     NA     NA     NA     NA
  L3‐1     0.03                 0.07          0.08                   346.3         418.1    413.0    1.7    2.4    2.9    2.6    1.9    1.7
  L3‐2     0.26                 0.41          0.24                   500.5         564.7    428.9    4.1    5.1    4.1    1.8    1.6    1.4
  L3‐3     0.10                 0.21          0.29                   485.8         495.9    629.4    2.5    3.0    3.8    1.9    2.0    2.0
  L3‐4     0.01                 0.00          0.01                   361.2         313.8    272.4    2.0    1.9    1.6    5.8    2.1    2.0
  L3‐5     0.02                 0.01          0.01                   201.3         167.3    153.6    2.1    2.5    2.2    2.1    2.2    2.3
  L3‐6     NA                   NA            NA                     NA            NA       NA       NA     NA     NA     NA     NA     NA
  L3‐7     1.50                 1.50          NA                     1960.0        1890.0   NA       NA     NA     NA     NA     NA     NA

A blood test was performed after the third/sixth vaccination or disease progression, whichever occurred first. Pt no., patient number; na, not available.
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Clinical outcomes {#cas12919-sec-0013}
-----------------

Of the 21 patients evaluated in this study, six had stable disease (SD) and 15 showed PD (Table [6](#cas12919-tbl-0006){ref-type="table-wrap"}). Six cases with SD were observed after the sixth vaccination (3, 2 and 1 patient received 10, 20 and 30 mg). Among the six patients with SD, two had esophageal squamous cell carcinoma, two had colorectal adenocarcinoma, one had gastric adenocarcinoma, and one had anal canal squamous cell carcinoma. Three of five SD patients, who had been allowed to continue with peptide vaccinations on compassionate grounds, experienced a long, consistent SD for 26, 35 and 37 weeks, respectively. One patient (L1‐4) with metastatic esophageal squamous cell carcinoma showed an initial disease progression, followed by regression at 3.5 months after initial treatment (Fig. [2](#cas12919-fig-0002){ref-type="fig"}).

###### 

Patient characteristics, clinical response and immune response

  Patient number   Dose of KRM‐10 (mg)   Age/gender   PS   Primary lesion    Prior therapy                                   Number of vaccinations   Response[†](#cas12919-note-0007){ref-type="fn"}   CTL response[‡](#cas12919-note-0007){ref-type="fn"}   IgG response   OS (m)   Between (*x*) and (*y*), (week)   Post‐treatment
  ---------------- --------------------- ------------ ---- ----------------- ----------------------------------------------- ------------------------ ------------------------------------------------- ----------------------------------------------------- -------------- -------- --------------------------------- ------------------
  L1‐1             10                    71/M         1    Esophagus         FU, CDDP, RT, Ope                               14                       SD                                                \+                                                    −              13.9     26                                BSC
  L1‐2             10                    77/M         1    Esophagus         FU, CDDP, Ope, PTX                              6                        PD                                                \+                                                    −              8.7      6                                 BSC
  L1‐3             10                    63/M         1    Stomach           S‐1, CDDP, CPT, MMC                             6                        PD                                                −                                                     −              2.5      6                                 BSC
  L1‐4             10                    72/F         0    Esophagus         FU, CDDP, RT, PTX                               16                       SD                                                \+                                                    −              20.1     35                                CDK4/6 inhibitor
  L1‐5             10                    72/M         1    Stomach           Ope, FU, S‐1, L‐OHP                             6                        SD                                                −                                                     −              7.6      6                                 RT
  L1‐6             10                    68/M         0    Esophagus         FU, CDDP, MEK inhibitor, PTX                    6                        PD                                                \+                                                    \+             3.0      6                                 BSC
  L2‐1             20                    62/M         1    Colorectum        S‐1, CPT, Capecitabine, L‐OHP, BV, Pmab, Cmab   6                        PD                                                \+                                                    \+             7.6      6                                 BSC
  L2‐2             20                    72/M         1    Small intestine   Ope, FU, L‐OHP                                  5                        PD                                                NA                                                    NA             3.4      5                                 BSC
  L2‐3             20                    72/F         0    Colorectum        Ope, FU, L‐OHP, BV, CPT                         6                        PD                                                −                                                     \+             9.8      6                                 Regorafenib
  L2‐4             20                    70/F         1    Colorectum        Ope, UFT, FU, L‐OHP, BV, CPT, Pmab              8                        SD                                                \+                                                    \+             5.1      11                                BSC
  L2‐5             20                    49/F         0    Colorectum        Ope, Capecitabine, CPT, S‐1, L‐OHP              6                        PD                                                \+                                                    \+             4.0      6                                 BSC
  L2‐6             20                    61/M         0    Colorectum        Ope, S‐1, CPT, BV, Capecitabine, L‐OHP          3                        PD                                                NA                                                    NA             1.4      3                                 BSC
  L2‐7             20                    69/M         0    Colorectum        Ope, FU, CPT, Pmab, L‐OHP, BV, TAS102, Cmab     9                        SD                                                \+                                                    −              19.9     13                                Regorafenib
  L2‐8             20                    77/M         0    Stomach           S‐1, CDDP, Ope, CPT, PTX                        6                        PD                                                \+                                                    −              6.6      6                                 BSC
  L3‐1             30                    65/M         1    Colorectum        Ope, FU, L‐OHP, BV                              6                        PD                                                −                                                     \+             6.2      6                                 BSC
  L3‐2             30                    75/F         1    Colorectum        FU, L‐OHP, CPT, Cmab                            6                        PD                                                \+                                                    \+             3.7      6                                 BSC
  L3‐3             30                    61/M         1    Colorectum        Ope, UFT, FU, L‐OHP, CPT                        6                        PD                                                −                                                     −              12.8     6                                 Regorafenib
  L3‐4             30                    72/M         0    Stomach           S‐1, CDDP, PTX                                  6                        PD                                                \+                                                    −              10.2     6                                 CPT
  L3‐5             30                    63/F         1    Anal canal        UFT, RT, Ope, FU, CDDP, CPT, Pmab, PTX          17                       SD                                                −                                                     −              16.6     37                                Ope
  L3‐6             30                    66/M         0    Colorectum        Ope, RT, S‐1, L‐OHP, BV, CPT                    2                        PD                                                NA                                                    NA             6.1      2                                 CPT+Cmab
  L3‐7             30                    59/F         1    Stomach           S‐1, CDDP, Ope, DTX, CPT                        6                        PD                                                \+                                                    \+             10.8     6                                 BSC

†Clinical responses were evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1. ‡CTL responses were classified according to the number of peptides inducing positive CTL responses in patients. CPT, irinotecan; CTL, cytotoxic T lymphocytes; F, female; M, male; OS(m), overall survival (months); PD, progressive disease; PS, performance status; SD, stable disease; (*x*), start of vaccination; (*y*), completion of last treatment. Prior therapy: BV, bevacizumab; CDDP, cisplatin; Cmab, cetuximab; DTX, docetaxel; FU, 5‐fluorouracil; L‐OHP, oxaliplatin; MMC, mitomycin C; Ope, surgery; Pmab, panitumumab; PTX, paclitaxel; RT, radiation; UFT, tegafur/uracil.
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![A closed arrow indicates the initial progression (2 months), followed by regression (3.5 months), and then progression again (7 and 9 months) of a pulmonary lesion in a patient (L1‐4). An open arrow shows a new pulmonary lesion.](CAS-107-590-g002){#cas12919-fig-0002}

Discussion {#cas12919-sec-0014}
==========

Optimal clinical outcomes have not ensued after the testing of cancer vaccines in the past two decades, with a consequent lack of drug approvals.[5](#cas12919-bib-0005){ref-type="ref"}, [6](#cas12919-bib-0006){ref-type="ref"}, [7](#cas12919-bib-0007){ref-type="ref"} Therefore, we aimed to develop and test different doses of a new type of CTL‐epitope peptide vaccine consisting of 10 mixed peptides (KRM‐10) that can be applied to a majority of cancer patients with different HLA alleles. KRM‐10 was well tolerated at doses up to 30 mg of peptides (3 mg per peptide) in gastrointestinal cancer patients who were refractory to standard chemotherapy. The most common adverse event observed was an injection site reaction. DLT were not observed in all three cohorts during 6 weeks of treatment. In addition, no cumulative and delayed toxicities were observed during the use of KRM‐10 on compassionate grounds after its initial (six times) use. These apparent safety characteristics of KRM‐10 are consistent with previously conducted evaluations of peptide‐based cancer vaccines.[3](#cas12919-bib-0003){ref-type="ref"}, [4](#cas12919-bib-0004){ref-type="ref"}, [5](#cas12919-bib-0005){ref-type="ref"}, [6](#cas12919-bib-0006){ref-type="ref"}, [7](#cas12919-bib-0007){ref-type="ref"}, [10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}

Most previously conducted phase I studies of cancer vaccines failed to show either clear evidence of an appropriate dose setting or a definitive predictive biomarker, which, in turn, hampered the further development of clinical trials.[3](#cas12919-bib-0003){ref-type="ref"}, [4](#cas12919-bib-0004){ref-type="ref"}, [5](#cas12919-bib-0005){ref-type="ref"}, [6](#cas12919-bib-0006){ref-type="ref"}, [7](#cas12919-bib-0007){ref-type="ref"}, [10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"} The present study showed that both CTL and IgG responses, favorable markers for a cancer vaccine as reported previously,[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"} were more frequently increased after the vaccination of patients in the 20‐mg cohort as compared with the other two groups. In contrast, soluble inflammatory factors, including C‐reactive protein and haptoglobin, which are unfavorable markers for cancer vaccines as previously reported,[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}, [17](#cas12919-bib-0017){ref-type="ref"}, [18](#cas12919-bib-0018){ref-type="ref"} were somewhat increased after the vaccination of patients in the 10‐mg group. These results suggest that a dose of 20 mg of KRM‐10 should be recommended for any future phase II study for not only its observed safety but also because of the demonstration of having the most potent activity that augments the immune response, with minimal effects on soluble inflammatory factors among the three different doses tested.

However, of note, the 10‐mg group was dominated by advanced esophageal cancer patients, whereas the other groups were dominated by colorectal cancer patients. This difference might influence the immune responses to the KRM‐10. This issue shall be considered in the next step of clinical study, although each of these 10 peptides equally boosted the peptide‐specific immune responses for the majority (\>more than 50%) of both advanced esophageal cancer and colorectal cancer patients, who received these peptides in the clinical study of personalized peptide vaccination regimens (unpublished results).[10](#cas12919-bib-0010){ref-type="ref"}

It has been well documented that efficiently primed CTL induced by cancer vaccines often lose their responsiveness to tumor cells, primarily due to immunosuppression by Tregs and myeloid‐derived suppressor cell (MDSC), and also by T cell inhibition mediated by checkpoint molecules, such as CTL‐associated protein 4 (CTLA‐4) and programmed cell death 1 (PD‐1).[1](#cas12919-bib-0001){ref-type="ref"}, [2](#cas12919-bib-0002){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"} Acute‐phase inflammatory factors, including C‐reactive protein, haptoglobin, serum amyloid A and IL‐6, are well known soluble mediators for Treg‐induced and MDSC‐induced suppression against vaccine‐induced immune activation.[10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}, [14](#cas12919-bib-0014){ref-type="ref"}, [17](#cas12919-bib-0017){ref-type="ref"}, [18](#cas12919-bib-0018){ref-type="ref"} Precise mechanisms involved in the phenomenon of lower and higher peptide doses (10 and 30 mg of peptides), but not the modest dose (20 mg of peptides), inducing lower levels of CTL and IgG responses are presently unknown. These results, however, are consistent with a recently conducted phase I dose setting study of a 20‐mixed peptide vaccine for advanced hormone‐refractory prostate cancer patients in which lower and higher peptide doses (6 and 60 mg total doses with 0.3 and 3 mg of each peptide, respectively), but not a modest dose (20 mg total dose with 1 mg of each peptide), induced lower levels of CTL and IgG responses.[14](#cas12919-bib-0014){ref-type="ref"} One possible explanation could be that both lower, as well as excess, amounts of antigens often induce immune tolerance or suppressive regulating activity rather than immune activation, respectively. Although this issue will be further investigated, these results suggest that approximately 20 mg of the CTL epitope peptide per injection would be appropriate for peptide‐specific immune induction.

At least 4 of the 10 mixed peptides were matched to each of the 21 enrolled patients in terms of HLA‐class IA types, as shown in Table [3](#cas12919-tbl-0003){ref-type="table-wrap"}. After vaccination with 10 mixed peptides, HLA‐matched peptides would be recognized by CTL, but peptides with differing HLA alleles would, theoretically, be metabolized without any apparent biological effects. There may be some concern in regard to the competition between peptides in the KRM‐10 peptide mix to bind to the same HLA restriction element. Although peptide competition was not directly evaluated here, we found that the frequency of a CTL response to each of the 10 peptides was similar to that of the 10‐peptide mix. This is consistent with what has been reported for other multiple peptide vaccines, suggesting that competition for binding to the same HLA molecule is not significant enough to limit immunogenicity.[14](#cas12919-bib-0014){ref-type="ref"}, [19](#cas12919-bib-0019){ref-type="ref"} Indeed, Hazama *et al*.[20](#cas12919-bib-0020){ref-type="ref"} have also recently reported that the CTL induction was not different between separate injections and mixed injections.

Clinical efficacy was not an endpoint of this small scale, phase I study. However, information on clinical efficacy is of the utmost importance in the development of a cancer vaccine. The histological type of squamous cell cancer came from the esophagus or anal canal, while adenocarcinoma was derived from the stomach, intestine or colorectal tissues. Patients did not exhibit a complete or partial response, but some patients displayed SD, regardless of a previous history of intensive treatment for gastrointestinal cancers. All three patients with a prolonged SD were being treated for squamous cell carcinomas of the esophagus and anal canal. Although the reasons involved in this issue were presently unclear, EGFR~800--80~ contained in the KRM‐10 might be in part involved in better responses of three squamous cell carcinomas patients, because squamous cell cancer of the esophagus showed higher frequency of EGFR expression, compared to adenocarcinoma of stomach or colorectum, as shown in Table [1](#cas12919-tbl-0001){ref-type="table-wrap"}, and better clinical efficacy of anti‐EGFR therapy for squamous cell cancer of the esophagus or head and neck is often reported. In contrast, colorectal cancer patients entered in this study mostly received anti‐EGFR therapy and became refractory to the treatment. Further studies are needed to better understand this issue.

The progression free survival and overall survival of a few patients under KRM‐10 vaccination was somewhat longer than those under best supportive care. No patients received other than KRM‐10 during the stable disease, suggesting the contribution of KRM‐10 vaccination to at least progression free survival among a part of the patients. After disease progression, 13 of 21 patients received only best supportive care, four patients received targeted therapies, and the other four received other anti‐cancer therapies, as shown in Table [6](#cas12919-tbl-0006){ref-type="table-wrap"}. Clinical benefits should be carefully evaluated in the next step of clinical trials.

It is also of importance to note the limitations of the present study. First, advanced gastrointestinal cancer patients had a relatively large tumor burden resistant to standard therapies. Second, the median number of times of vaccination was only six in this study, which may not have been sufficient for the induction of potent immune responses with regard to the history of previously conducted peptide‐based cancer vaccines.[5](#cas12919-bib-0005){ref-type="ref"}, [6](#cas12919-bib-0006){ref-type="ref"}, [7](#cas12919-bib-0007){ref-type="ref"}, [10](#cas12919-bib-0010){ref-type="ref"}, [11](#cas12919-bib-0011){ref-type="ref"}, [12](#cas12919-bib-0012){ref-type="ref"}

In conclusion, a 20‐mg KRM‐10 vaccine was determined to be a recommended phase II dose because of its safety and because it exhibited the most potent activity to augment the immune response of the three different doses tested.
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Table S1. HLA restriction of 10 peptides of KRM‐10.
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Click here for additional data file.

The authors wish to thank Yushi Nagai and Chika Asami for data management, Tomoyo Manita and Tsukasa Shinohara for providing technical assistance, and Mayumi Ayabe and Kumiko Hirayama for collecting clinical data. This study was supported in part by a grant from a research program of The Project for Development of Innovative Research on Cancer Therapeutics (P‐DIRECT) from The Ministry of Education, Culture, Sports, Science and Technology of Japan, and a grant from the Sendai Kousei Hospital.
